Chen Qiushi, Ayer Turgay, Nastoupil Loretta J, Seward Miray, Zhang Hongzheng, Sinha Rajni, Flowers Christopher R
H Milton Stewart School of Industrial & Systems Engineering , Georgia Institute of Technology, Atlanta, GA 30332, USA.
Int J Hematol Oncol. 2012 Oct;1(1):35-45. doi: 10.2217/ijh.12.7.
Follicular lymphoma (FL) can vary markedly in its initial presentation, and no single standard approach for its initial management has been adopted. Available options for the initial management of FL include watchful waiting, radiation, single-agent rituximab and combination of rituximab and chemotherapy with strategies segregated for patients who have low and high tumor burden disease based on established criteria. However, marked debate occurs regarding the role of watchful waiting in the modern era for low tumor burden, asymptomatic patients, the optimal timing of rituximab, the selection of chemotherapy regimen to partner with rituximab in high tumor burden patients, and strategies for the management of relapsed disease. We provide an evidence-based discussion on these and other issues regarding the management of FL, and propose a mathematical modeling approach for addressing some of these questions.
滤泡性淋巴瘤(FL)的初始表现差异显著,目前尚未采用单一的标准初始治疗方法。FL初始治疗的可用选项包括观察等待、放疗、单药利妥昔单抗以及基于既定标准将利妥昔单抗与化疗联合应用于低肿瘤负荷和高肿瘤负荷疾病患者的策略。然而,对于观察等待在现代低肿瘤负荷、无症状患者中的作用、利妥昔单抗的最佳使用时机、高肿瘤负荷患者中与利妥昔单抗联合使用的化疗方案选择以及复发疾病的管理策略等问题,存在激烈的争论。我们对这些以及其他关于FL治疗的问题进行基于证据的讨论,并提出一种数学建模方法来解决其中一些问题。